Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

Novartis AGTrade
abrdn Physical Palladium Shares ETFTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs abrdn Physical Palladium Shares ETF — how do they compare? Novartis AG trades at $152.83 (market cap $295.37B), while abrdn Physical Palladium Shares ETF trades at $25.15. The key difference: Novartis AG pays a 3.07% dividend while abrdn Physical Palladium Shares ETF pays none, and Novartis AG is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.

NVSPALL
Market Cap
$295.37B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$168.62$37.18
52-Week Low
$119.31$19.96
Enterprise Value
$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

abrdn Physical Palladium Shares ETF

PALL (Aberdeen Physical Palladium Shares ETF) trades at $25.15, showing minimal daily movement with a 0.16% gain. Technical indicators show a bullish trend with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. The ETF recently underwent a 1:5 stock split effective May 18, 2026, adjusting share structure while maintaining exposure to physical palladium.

PALL offers exposure to palladium's supply-demand dynamics amid current price weakness, with analysts viewing the 47% decline from January 2026 highs as a potential buying opportunity. Key risks include Federal Reserve policy uncertainty and industrial demand fluctuations. The ETF's physical backing provides direct commodity exposure, though palladium's volatility requires careful risk management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About abrdn Physical Palladium Shares ETF

PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.

Read more on PALL